Navigation Links
Internet and new drugs: A challenge for public health
Date:5/8/2012

Barcelona, 8th May 2012. A group of researchers from the IMIM (Hospital del Mar Research Institute) and from the INAD (Hospital del Mar Neuropsychiatry and Addictions Institute) has participated in an international study aiming to give a general overview at a chemical, pharmacological and behavioural level of a recently appeared new chemical compound, according to the Recreational Drugs European Network, as a new abused drug: methoxetamine (MXE).

This new drug, similar to ketamine, is a dissociative drug, meaning it distorts visual and auditory perceptions making one feel separated or "dissociated" from the environment and from oneself, without a loss of consciousness. As the researchers explain "It seems to increase the sense of humour and has strong hallucinogenic properties".

The researchers add that "one of the dangers of these new compounds such as MXE is that most of them are not approved for human consumption and consuming them could be associated to an unknown number of side effects and adverse reactions that have not been described". Information at a toxicological or pharmacological level as well as on users is nearly nonexistent.

In this sense, these new compounds are becoming more and more sophisticated, are usually synthesized in clandestine laboratories, simply by modifying the molecular structure of the substances that are already controlled, with the aim of maintaining a lack of regulation for the largest possible time, and are rapidly spread over the Internet.

In the specific case of MXE, it would seem that its toxicity and side effects would be similar to those of ketamine, a dissociative anaesthetic used in medicine and veterinary that, when used in sub-anaesthetic doses, leads to a range of effects going from a light drunkenness, perceptive stimulation or distortion to the appearance of death-like experiences or body splitting. The main difference when comparing MXE to ketamine, however, is that the duration and intensity of these effects are longer lasting.

In the study, researchers have detected that stores selling this drug over the internet, are advertising it and selling it as a legal alternative to ketamine, since it can be purchased legally without needing a veterinary licence and at a better price. This has meant that it has become extremely popular among consumers and has affected the risk perception associated to consumption, given that many consumers associate legality to safety.

The combination of new synthetic abusive drugs and the speed at which information is spread over the Internet have caused the experts' concern for toxicological, pharmacological or public health issues increase. Experts consider it necessary to have a greater collaboration at an international level to tackle this phenomenon consisting of easily accessible psychoactive drugs over the internet, which is growing rapidly at present.
'/>"/>

Contact: Marta Calsina
mcalsina@imim.es
34-933-160-680
IMIM (Hospital del Mar Research Institute)
Source:Eurekalert

Related biology news :

1. CCNY researchers study scientific collaboration in age of internet
2. Internet catches updated butterfly and moth website
3. Pecan ipmPIPE: Harnessing the Internet for stakeholders in production agriculture
4. Knock-out drugs: Narrow window for detection
5. Barcelona Declaration 2008: Challenges and Pathways to Earth Sustainability
6. Research challenges conventional notions about salmon survival
7. Siblings of mentally disabled face own lifelong challenges, according to researchers
8. First-ever socioeconomic study on coral reefs points to challenges of coastal resource management
9. Finalists announced in the Elsevier Grand Challenge
10. Invasive plants challenge scientists in face of environmental change
11. Leading research agencies announce new international competition: "The digging into data challenge"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced it has issued a scientific white paper entitled “Results from ... series of commentaries from ProMIS’s scientific team offering insight into the Company’s product ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... productivity traits and nutritional products, today announced their collaboration to achieve ... China to the United States ... ...
(Date:2/22/2017)... and SAN DIEGO , Feb. ... "Company") (OTCQB:CELZ) announced today expansion of its translational ... cell product through establishment of laboratory facilities in ... at the San Diego BioLabs facility, a biotechnology ... Novartis, and Sanofi. In November 2016, ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, ... health applications, announced a partnership with Redox, a leader in cloud-based healthcare integration ... clinical systems while keeping data secure in the cloud. , The digital health ...
Breaking Biology Technology: